Education
About Us
Working with TipRanks
Follow Us
ArcticZymes Technologies ASA (DE:B4V)
:B4V
B4V Stock Chart & Stats
€2.39
-€0.02(-1.33%)
At close: 4:00 PM EST
€2.39
-€0.02(-1.33%)
Day’s Range― - ―
52-Week Range€1.04 - €2.62
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€122.50M
Enterprise Value€641.27M
Total Cash (Recent Filing)€242.70M
Total Debt (Recent Filing)€7.95M
Price to Earnings (P/E)740.6
Beta0.68
Next Earnings
Nov 06, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding51,071,390
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ArcticZymes Technologies ASA News
B4V FAQ
What was ArcticZymes Technologies ASA’s price range in the past 12 months?
ArcticZymes Technologies ASA lowest stock price was €1.04 and its highest was €2.62 in the past 12 months.
What is ArcticZymes Technologies ASA’s market cap?
ArcticZymes Technologies ASA’s market cap is €122.50M.
When is ArcticZymes Technologies ASA’s upcoming earnings report date?
ArcticZymes Technologies ASA’s upcoming earnings report date is Nov 06, 2025 which is in 7 days.
How were ArcticZymes Technologies ASA’s earnings last quarter?
ArcticZymes Technologies ASA released its earnings results on Aug 14, 2025. The company reported €0.005 earnings per share for the quarter, beating the consensus estimate of €0.002 by €0.003.
Is ArcticZymes Technologies ASA overvalued?
According to Wall Street analysts ArcticZymes Technologies ASA’s price is currently Overvalued.
Does ArcticZymes Technologies ASA pay dividends?
ArcticZymes Technologies ASA does not currently pay dividends.
What is ArcticZymes Technologies ASA’s EPS estimate?
ArcticZymes Technologies ASA’s EPS estimate is <0.01.
How many shares outstanding does ArcticZymes Technologies ASA have?
ArcticZymes Technologies ASA has 51,071,390 shares outstanding.
What happened to ArcticZymes Technologies ASA’s price movement after its last earnings report?
ArcticZymes Technologies ASA reported an EPS of €0.005 in its last earnings report, beating expectations of €0.002. Following the earnings report the stock price went up 38.608%.
Which hedge fund is a major shareholder of ArcticZymes Technologies ASA?
Currently, no hedge funds are holding shares in DE:B4V
Company Description
ArcticZymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.
Technical Analysis
Options Prices
Currently, No data available
---